Tirzepatide Dosage Chart: Complete Titration Schedule for Safe, Provider-Directed Use

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Published / Reviewed July 24, 2026

Written by Sam Brooks, health writer at Beverly Hills Rejuvenation Center. Reviewed for clinical accuracy by the BHRC clinical team — board-certified physicians and licensed medical providers who supervise the center’s medically directed weight-management and metabolic programs.

Medical disclaimer: This guide is educational and is not medical advice. Tirzepatide (marketed as Mounjaro and Zepbound) is a prescription medication that must be prescribed, dosed, and monitored by a licensed clinician. The numbers below describe the FDA-approved labeling and published trial protocols so you can have an informed conversation with your provider — they are not instructions to self-dose, self-inject, or adjust a prescription on your own. Never start, stop, or change a tirzepatide dose without your prescribing clinician.

Quick Tirzepatide Dosing Summary

What is the tirzepatide dosing schedule? Tirzepatide starts at 2.5 mg injected under the skin once weekly for 4 weeks — a starter dose only. The dose then increases in 2.5 mg steps no sooner than every 4 weeks, working through 5, 7.5, 10, and 12.5 mg. Recognized maintenance doses are 5, 10, or 15 mg once weekly, and 15 mg is the maximum. Every step is provider-directed.

Quick reference:

The rest of this guide unpacks each row: the week-by-week ladder, how maintenance targets differ for weight loss versus type 2 diabetes versus sleep apnea, what to do when a dose increase is intolerable, and the mg-to-unit math behind branded pens. Schedule a Peptide Therapy Consultation if you want a clinician to build a plan around your labs and goals.

What Is Tirzepatide (Mounjaro and Zepbound)?

Tirzepatide is a once-weekly injectable medication and the first in a class of dual incretin agonists. It is manufactured by Eli Lilly and sold under two brand names — Mounjaro and Zepbound — that contain the identical molecule but carry different FDA-approved indications. Of the current generation of GLP-1-based metabolic drugs, tirzepatide is among the most rigorously studied and is fully FDA-approved, which makes it one of the safest and best-characterized options in the category.

How Tirzepatide Works (Dual GIP and GLP-1 Action)

Tirzepatide activates two gut-hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Together these actions enhance glucose-dependent insulin secretion, slow gastric emptying, reduce appetite and food intake, and improve insulin sensitivity. The dual mechanism is thought to explain why tirzepatide produces larger average weight and glucose reductions than single-agonist GLP-1 drugs in head-to-head data.

Pharmacokinetics and the Once-Weekly Half-Life

Tirzepatide’s roughly 5-day elimination half-life is what makes once-weekly dosing possible and gives its schedule real forgiveness. After an injection, blood levels rise over about a day and then decline slowly across the week, so drug is always present at a stable, steady-state concentration once you have been on a given dose for several weeks. This long half-life also explains two practical realities: appetite and glucose effects do not switch on and off day to day, and it takes several doses at a new step before you feel that step’s full effect — another reason 4 weeks per level is the sensible minimum before judging tolerability or results.

Mounjaro vs Zepbound: Same Molecule, Different Indications

Mounjaro is FDA-approved to improve blood sugar (glycemic control) in adults with type 2 diabetes. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and — since December 2024 — for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The active ingredient, strengths, and titration rules are the same; the brand simply signals which condition it is prescribed and (usually) insured for. Throughout this guide, “tirzepatide” refers to both.

Branded Pens vs Compounded Tirzepatide

Branded Mounjaro and Zepbound ship as pre-filled, fixed-dose single-dose pens (and single-dose vials) — there is nothing to mix or measure. During the 2022–2024 GLP-1 shortage, some pharmacies compounded tirzepatide, but the FDA declared the tirzepatide shortage resolved in December 2024 and ended enforcement discretion for compounding in early 2025. Compounded tirzepatide is now legally restricted; see the regulatory section below. BHRC’s medically supervised programs use FDA-approved products under physician direction.

Tirzepatide Dosage Chart: Week-by-Week Titration Schedule

The single most searched question about this drug is the titration schedule — the “dosage chart.” Tirzepatide is deliberately titrated slowly because the gastrointestinal side effects that come with GIP/GLP-1 therapy are largely dose- and speed-dependent. Escalating too fast is the most common avoidable reason people abandon treatment.

The Standard FDA Titration Ladder (2.5 to 15 mg)

The FDA label describes a consistent ladder regardless of brand: begin at 2.5 mg once weekly for 4 weeks, then increase in 2.5 mg increments no more frequently than every 4 weeks until you reach an effective, tolerated dose — up to the 15 mg maximum. The six strengths map onto the ladder like this:

The 2.5 mg increment size and the 4-week minimum interval are the two rules a provider will not rush. Many patients stop climbing before 15 mg because a lower dose already controls appetite or blood sugar — the goal is the lowest effective dose, not the maximum.

Full Week-by-Week Titration Table (Weeks 1–24)

Below is the fastest schedule the label permits — moving up at every 4-week window. This is a reference for what “by the book” looks like; real schedules are frequently slower because providers hold at a dose whenever side effects or results warrant.

Reaching 15 mg therefore takes a minimum of about 20 weeks from the first 2.5 mg dose (you complete week 20 on 12.5 mg and step up in week 21). If any dose needs to be repeated for tolerability, the timeline extends accordingly — which is normal and expected.

Why 2.5 mg Is a Starting Dose, Not a Treatment Dose

The FDA label is explicit that 2.5 mg is for initiation only and is “not intended for glycemic control” (Mounjaro) or as a weight-management maintenance dose (Zepbound). Its purpose is to let the gut acclimate to slowed gastric emptying so that nausea, and constipation are milder as the dose rises. Judging the drug’s effectiveness at 2.5 mg is premature — meaningful appetite and glucose effects generally build at 5 mg and above.

Starter Doses vs Maintenance Doses

It helps to separate the strengths into two buckets. The recognized maintenance doses are 5, 10, and 15 mg. The 2.5, 7.5, and 12.5 mg strengths are primarily titration steps you pass through on the way up (2.5 mg is the mandatory starter; 7.5 and 12.5 mg are half-steps that smooth the climb). A patient can, however, be maintained on 7.5 or 12.5 mg long-term if that dose is what controls their symptoms with acceptable tolerability — this is a clinical judgment, not a fixed rule.

A More Conservative (Slower) Titration Approach

The week-by-week table above is the fastest schedule allowed — but “allowed” and “ideal for you” are different things. Many clinicians deliberately titrate more slowly, holding an extra 4 weeks (or more) at a dose that is working or that caused notable side effects. A slower ladder trades time for tolerability, and for a chronic therapy that trade is often worth it. A conservative schedule might, for example, spend 8 weeks at 2.5 mg, or pause at 5 mg for two months while weight and appetite respond, before considering any further increase. Nothing about tirzepatide requires reaching a higher dose on a deadline.

Individualizing the Ladder to the Patient

The right titration for a given person depends on their goal, starting point, side-effect sensitivity, and how they are responding. Someone tolerating the medication well and still short of their target may climb steadily; someone getting strong results at 5 mg with occasional nausea may sit there indefinitely; someone with a sensitive stomach may benefit from the slowest possible ascent. This is why a printed chart is a starting map, not the route — the route is drawn by your prescriber, in response to how your body actually reacts. Bringing a symptom-and-results log to each visit makes that individualization far more precise.

Maintenance Dose Targets by Indication

Most competitor “dosage charts” present a single generic ladder. In practice, the target maintenance dose depends on why tirzepatide is prescribed. The ladder to get there is identical, but the destination differs for weight loss, type 2 diabetes, and sleep apnea.

Zepbound Maintenance for Weight Loss

For chronic weight management, the recommended maintenance doses are 5, 10, or 15 mg once weekly. 5 mg is recognized as a maintenance dose for the weight-loss indication specifically, which gives lower-tolerance patients a legitimate stopping point. In the SURMOUNT-1 trial, higher maintenance doses produced greater average weight loss, so providers and patients often weigh added benefit against added side-effect burden when deciding whether to keep climbing past 5 or 10 mg.

Mounjaro Maintenance for Type 2 Diabetes

For type 2 diabetes, tirzepatide is titrated to an effective, tolerated dose that reaches the patient’s blood-sugar targets (often tracked with A1C). Maintenance doses are 5, 10, or 15 mg once weekly. Because glycemic goals vary, some people reach target at 5 or 10 mg and never need 15 mg; others titrate fully. The dose is individualized to glucose control, not to a preset number.

Tirzepatide Maintenance for Obstructive Sleep Apnea

The OSA indication (Zepbound) is different: the SURMOUNT-OSA trials studied only the two highest maintenance doses. Participants were titrated to their maximum tolerated dose of 10 mg or 15 mg once weekly — the doses at which the sleep-apnea benefit was demonstrated. So for OSA in adults with obesity, the therapeutic target is the high end of the ladder, reflecting the trial design rather than a lower option.

Maintenance Target Comparison Table

This table is one of the most important on the page: the same drug, the same climb, but three different “finish lines.” Your provider chooses the destination based on your diagnosis, response, and tolerability.

How to Increase Your Tirzepatide Dose Safely

“When do I go up?” and “how do I increase my tirzepatide dose?” are among the most common patient questions. The mechanics are simple; the judgment is clinical.

The 4-Week Rule

Never escalate faster than every 4 weeks. The 4-week interval gives the gut time to adapt to each new level of gastric slowing before the next increase. Moving up early sharply raises the odds of nausea, and dehydration — the very side effects the slow ladder exists to prevent.

When to Move Up (and When to Stay)

A dose increase is generally considered when you have completed at least 4 weeks at the current dose, side effects are mild or resolved, and you are not yet at your goal (adequate appetite control, weight trajectory, glucose targets, or OSA response). If a lower dose is already delivering results with good tolerability, staying there is entirely appropriate — the lowest effective dose is the objective. This decision belongs to your prescriber, informed by how you feel and what your numbers show.

How Long It Takes to Reach Maintenance

At the fastest label-permitted pace, reaching the 15 mg maximum takes about 20–24 weeks (roughly 5–6 months). Reaching a 5 mg or 10 mg maintenance dose is faster — about 4 weeks and 12 weeks respectively. Because many patients repeat a dose for tolerability, planning for a slightly longer runway than the minimum is realistic and healthy.

What to Do If You Can’t Tolerate a Dose Increase

This is the section most “dosage chart” articles skip, and it is where patients most need guidance. Struggling with a dose is common and manageable — it is not a sign the medication has failed.

Option 1: Stay at Your Current Dose

The simplest response to a rough dose increase is to not increase — hold at the last dose you tolerated well for additional weeks until symptoms settle, then reattempt the step later. There is no requirement to keep climbing on a fixed calendar, and there is no penalty for spending extra time at 5, 7.5, or 10 mg. Many people maintain excellent results without ever reaching 15 mg.

Option 2: Step Back Down

If a new, higher dose causes persistent nausea, or other intolerable effects, a provider may direct you to step back to the previous (well-tolerated) dose and stabilize before trying again more slowly. Dose reduction is a normal, expected part of titration — the FDA labeling anticipates pausing or lowering the dose to manage gastrointestinal reactions. Any step-down should be directed by your clinician, not improvised.

Managing GI Side Effects During Titration

Practical, provider-endorsed strategies that make each step easier include eating smaller portions, stopping at the first sign of fullness, avoiding greasy or very rich foods, staying well hydrated, and limiting alcohol. Persistent vomiting, signs of dehydration, or severe abdominal pain are reasons to contact your provider promptly rather than pushing forward. Report symptoms early — the plan can always be adjusted.

Tirzepatide Dose Conversion: mg to Units and mL

Because branded pens are pre-dosed, patients using Mounjaro or Zepbound never draw up a dose or count units — you inject the whole pen. Still, understanding the underlying volume and concentration clears up confusion, especially for anyone comparing products.

Branded Single-Dose Pen and Vial Concentrations

Each branded single-dose pen or single-dose vial delivers its labeled dose in 0.5 mL of solution. Because the volume is fixed at 0.5 mL, a higher-strength pen simply contains a more concentrated solution. The table below shows the concentration behind each strength.

mg to Units Reference Table

*On a U-100 insulin syringe, 0.5 mL always equals 50 units regardless of strength — because branded pens keep the volume constant and change the concentration. This column is illustrative only; branded pens are not drawn into a syringe, and you should never transfer a branded pen’s contents into an insulin syringe.

A Note on Compounded Tirzepatide Math

Compounded tirzepatide (now legally restricted — see below) is sometimes supplied as a multi-dose vial at a custom concentration, which is where “mg to units” confusion causes real dosing errors. If a vial is labeled, say, 10 mg/mL, then a 5 mg dose is 0.5 mL, which is 50 units on a U-100 syringe; a 2.5 mg dose is 0.25 mL, or 25 units. The general formula is: units = (dose in mg ÷ concentration in mg/mL) × 100. Never rely on this math yourself — vial concentrations vary, mislabeling happens, and only your prescriber should specify the exact draw. BHRC’s programs use FDA-approved fixed-dose products to remove this hazard entirely.

How Tirzepatide Is Administered

Tirzepatide is a subcutaneous (under-the-skin) injection given once weekly. Branded pens are designed for straightforward self-administration after training by a clinician or pharmacist.

Injection Site Selection

The three approved subcutaneous sites are the abdomen (keeping about two inches away from the navel), the front of the thigh, and the back of the upper arm. Rotating sites each week — and rotating spots within a site — reduces the chance of lumps, irritation, or lipohypertrophy. You do not need to match the injection site to any particular body area; absorption is comparable across the approved sites.

Subcutaneous Injection Technique (Step by Step)

1. Wash your hands and gather your pen, an alcohol swab, and a sharps container.
2. Check the pen: confirm the medication name, strength, and expiration date, and inspect the solution — it should be clear and colorless to slightly yellow, with no particles.
3. Choose and clean a site (abdomen, thigh, or upper arm) with the alcohol swab and let it dry.
4. Remove the pen’s base cap and place the flat, clear base firmly against the skin.
5. Unlock and press the injection button as directed by the device instructions; hold the pen in place until the dose finishes (typically until the second click and the gray plunger is visible).
6. Remove the pen, dispose of it in a sharps container, and note the date and site so you can rotate next week.

This is a general overview of the branded-pen process, not a substitute for the device’s Instructions for Use or the hands-on training your provider or pharmacist gives you. Always follow the specific instructions that come with your product.

A Note on Reconstitution

Branded Mounjaro and Zepbound require no reconstitution — they arrive as ready-to-use liquid pens and vials. Reconstitution (mixing a powder with bacteriostatic water) only applies to compounded lyophilized tirzepatide, which is now legally restricted and should only ever be prepared and dosed under direct clinical supervision. For that reason, this guide does not provide self-mixing instructions; if a program uses a reconstituted product, the exact bacteriostatic-water volume and resulting concentration must be specified and verified by the prescribing clinician.

Storage and Handling of Tirzepatide

Proper storage protects both the drug’s potency and your safety, and it is a common source of avoidable questions. The guidance below reflects branded Mounjaro and Zepbound labeling; always defer to the printed instructions on your specific product.

Refrigeration and Room-Temperature Limits

Store tirzepatide pens and vials refrigerated at 36–46°F (2–8°C) in the original carton to protect them from light, and do not freeze — a pen that has been frozen must be discarded even if it later thaws. If needed, branded product may be kept unrefrigerated at up to 86°F (30°C) for a limited window (commonly up to 21 days), after which it should be used or discarded. Never use medication that has been frozen, left in a hot car, or stored outside its labeled limits.

Traveling with Tirzepatide

For travel, keep pens in an insulated cooler bag with a cold pack (not directly against the pack, to avoid freezing), carry them in hand luggage rather than a checked bag where temperatures are uncontrolled, and bring the original packaging and your prescription information. Plan your weekly dose day around the trip using the “at least 3 days apart” rule if you need to shift it.

Safe Disposal

Used pens and needles go into an FDA-cleared sharps container — never loose in household trash. When the container is about two-thirds full, dispose of it according to your community’s guidelines or a mail-back program. Keep all supplies out of reach of children and pets.

Combining Tirzepatide with Lifestyle and Other Therapies

Tirzepatide is designed to work alongside, not instead of, foundational care. The comparison matrix earlier in this guide covers how it stacks up against other GLP-1-based drugs; this section addresses how it fits with the rest of a treatment plan.

Nutrition and Physical Activity

Every pivotal trial paired tirzepatide with a reduced-calorie diet and increased physical activity, and the labeling frames the drug as an adjunct to those measures. Because tirzepatide reduces appetite, protein intake and resistance training take on added importance to help preserve lean muscle during weight loss. A registered dietitian or the clinical team can tailor this alongside the medication.

Interaction with Diabetes Medications

When tirzepatide is added to existing diabetes therapy, insulin or sulfonylurea doses are often reduced by the prescriber to lower hypoglycemia risk. This is a coordinated, provider-managed adjustment — not something to change independently. Do not combine tirzepatide with another GLP-1 receptor agonist (such as semaglutide) unless a physician specifically directs it; doubling up on the class is not appropriate.

Where Other Peptides Fit

Patients sometimes ask about pairing tirzepatide with peptides aimed at recovery, growth-hormone support, or body composition. Any such combination is strictly a clinical decision that depends on your full profile and the evidence (or lack thereof) behind each agent. BHRC evaluates these on a case-by-case basis under physician supervision and never as a self-directed stack. Bring a complete list of everything you take to your consultation so interactions can be assessed.

Optimal Timing for Tirzepatide Administration

Tirzepatide’s once-weekly, long half-life makes timing forgiving compared with daily medications — but consistency still matters.

Same Day Each Week, Any Time of Day

Inject on the same day of the week, at any time of day, with or without food. Choosing a memorable anchor (for example, “Sunday morning”) improves adherence. There is no requirement to inject in the morning or on an empty stomach.

Switching Your Injection Day

The label allows changing your weekly injection day as long as at least 3 days (72 hours) separate two doses. That flexibility lets people shift the schedule around travel or life events without skipping a week.

Missed Dose Guidance

If a dose is missed, the general labeled guidance is to take it as soon as possible if there are more than 4 days (96 hours) until the next scheduled dose; if less than 4 days remain, skip the missed dose and resume the normal weekly schedule. Do not double up. Confirm the exact rule with your provider or the product instructions, since guidance is specific to your regimen.

Clinical Trial Evidence Behind the Dosing

The dosing ladder is not arbitrary — the maintenance doses of 5, 10, and 15 mg are precisely the doses tested in tirzepatide’s pivotal Phase 3 program.

SURMOUNT-1 (Weight Management)

In SURMOUNT-1, adults with obesity or overweight received 5, 10, or 15 mg of tirzepatide or placebo for 72 weeks. Average weight reductions were about 16% at 5 mg, 21% at 10 mg, and 22.5% at 15 mg, versus roughly 2–3% with placebo — the data behind why higher maintenance doses are offered for weight loss.

SURPASS-2 (Type 2 Diabetes)

In SURPASS-2, tirzepatide 5, 10, and 15 mg was compared head-to-head with semaglutide 1 mg in adults with type 2 diabetes. All three tirzepatide doses produced greater reductions in A1C and body weight than semaglutide 1 mg over 40 weeks, establishing the dual agonist’s glycemic potency across the maintenance range.

SURMOUNT-OSA (Obstructive Sleep Apnea)

In the two SURMOUNT-OSA trials, adults with moderate-to-severe OSA and obesity were titrated to their maximum tolerated dose of 10 or 15 mg for 52 weeks. Tirzepatide substantially reduced the apnea-hypopnea index — the measure of sleep-disordered breathing — supporting the December 2024 FDA approval and the high-dose target used for this indication.

Tirzepatide Safety Profile and Potential Side Effects

Tirzepatide is well characterized, but it carries meaningful warnings — including a boxed warning, the FDA’s most serious. The points below summarize the labeling; your provider will screen you against them before prescribing.

Boxed Warning: Thyroid C-Cell Tumors

Tirzepatide carries a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). In rodent studies, tirzepatide caused dose- and duration-dependent thyroid C-cell tumors; whether it causes these tumors in humans is not known. Because of this, tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled to report symptoms of a thyroid tumor — a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness. This warning is the single most important reason tirzepatide must be prescribed and supervised by a physician.

Common Side Effects (and How They Track with Dose)

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, and reduced appetite. Injection-site reactions, fatigue, and hair thinning are also reported. These effects are generally most pronounced during dose escalation and tend to ease at a stable dose — which is exactly why the slow, stepwise ladder exists.

Serious Risks: Pancreatitis, Gallbladder Disease, and Hypoglycemia

Serious but less common risks include acute pancreatitis (severe, persistent abdominal pain, sometimes radiating to the back — stop and seek care), acute gallbladder disease including gallstones, acute kidney injury (often from dehydration due to vomiting or diarrhea), diabetic retinopathy complications in some patients with diabetes, and severe gastrointestinal disease. Tirzepatide alone rarely causes low blood sugar, but the risk rises when it is combined with insulin or a sulfonylurea, so those doses may need to be reduced by the prescriber.

Suicidal Ideation and Mood Monitoring

As a class-wide precaution for weight-management medications, patients on tirzepatide should be monitored for the emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behavior, and should report such symptoms to their clinician. Anyone with a history of suicidal thoughts should discuss it with their provider before starting.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Known serious hypersensitivity to tirzepatide or any of its components.
• Pregnancy is a further important consideration — tirzepatide is generally not recommended during pregnancy, and effective contraception is advised; discuss family planning with your provider, as oral contraceptives may be less effective around dose changes.

Drug Interactions

Because tirzepatide slows gastric emptying, it can affect the absorption of oral medications. Two practical interactions stand out: insulin and sulfonylureas raise hypoglycemia risk (doses may need lowering), and oral contraceptives may be less reliable after starting tirzepatide or after a dose increase — a backup or non-oral method is often advised for a period. Give your provider a full medication list before starting.

Tirzepatide vs Other GLP-1 Peptides

Patients frequently ask how tirzepatide compares with semaglutide (its main competitor) and with retatrutide (a newer investigational agent). The matrix below summarizes the differences that matter for dosing and expectations.

For a deeper comparison, see our companion semaglutide dosing guide and retatrutide dosing guide, and the semaglutide therapy and tirzepatide therapy program pages. Retatrutide remains investigational and is presented here for education only, not as an available BHRC therapy.

What to Expect: Tirzepatide Results Timeline

Because the dose climbs gradually, results build gradually too — a common source of early frustration for people expecting immediate change. Setting realistic expectations against the titration schedule helps patients stay the course.

The First Month (2.5 mg)

During the 2.5 mg initiation month, the main “result” is adjustment, not transformation. Many people notice modestly reduced appetite or earlier fullness, and some initial GI side effects. Meaningful weight or glucose change at this dose is not expected, and its absence is not a sign the drug is failing.

Months 2–4 (5–10 mg)

As the dose reaches active levels, appetite suppression typically becomes more consistent and early weight loss or improved blood-sugar readings emerge. In the diabetes trials, A1C reductions were well established across these doses; in weight trials, the loss curve steepens as the maintenance dose is reached.

Months 5–12 and Beyond (Maintenance)

The largest average changes accrue over the following months at a stable maintenance dose. In SURMOUNT-1, weight reductions of 16–22.5% were measured at 72 weeks — roughly a year and a half — underscoring that tirzepatide is a long-term therapy, not a quick fix. Benefits generally persist while treatment continues; stopping the medication often leads to partial weight regain, which is why the plan and its duration are decided with your provider.

Who Should Consider Tirzepatide Therapy?

Tirzepatide is generally considered, under a physician’s evaluation, for adults who fit an FDA-approved indication: type 2 diabetes needing better glycemic control (Mounjaro); obesity, or overweight with a weight-related condition, for chronic weight management (Zepbound); or moderate-to-severe obstructive sleep apnea with obesity (Zepbound). It is meant to accompany, not replace, nutrition, activity, and — for OSA — other clinically indicated care. It is not appropriate for anyone with the contraindications above, and candidacy always depends on a full medical and family history, current medications, and lab work.

A thorough evaluation typically reviews your BMI and weight history, A1C and metabolic labs, thyroid and family cancer history (given the boxed warning), gallbladder and pancreatitis history, current prescriptions, and — where relevant — pregnancy plans and mental-health history. Tirzepatide is also generally reserved for adults; it is not established for children, and older adults or those with kidney concerns may need closer monitoring during titration. A consultation is the only reliable way to know whether it fits you, and it is also where realistic goals and a monitoring plan get set before the first dose.

Monitoring Progress and Adjusting Your Protocol

Because tirzepatide is titrated to effect, ongoing monitoring is what keeps it both safe and productive. Depending on the indication, a clinician typically tracks weight and waist trends, A1C and glucose for diabetes, blood pressure, kidney function and hydration, and — for OSA — sleep-study measures and symptoms. Side-effect check-ins guide the pace of escalation: good tolerability supports moving up, while significant symptoms support holding or stepping down. The plan is meant to be revisited, not set once and forgotten. If you feel a dose isn’t working, the answer is a provider conversation, not a self-adjustment.

Follow-up cadence is usually tighter during titration — often every 4 weeks, aligned with each potential dose change — and can space out once a stable maintenance dose is reached. Between visits, keeping a simple record of your dose, injection dates and sites, weight or glucose readings, and any side effects gives your provider the data to fine-tune the plan. Certain symptoms warrant contacting your clinician promptly rather than waiting for the next appointment: severe or persistent abdominal pain, signs of dehydration, symptoms of low blood sugar when on insulin or a sulfonylurea, or any of the thyroid-tumor warning signs described earlier.

Is Tirzepatide FDA-Approved? Legal & Regulatory Status (2026)

As of July 24, 2026, tirzepatide is fully FDA-approved — one of the most robust regulatory positions among metabolic peptides.

Approved Indications

• Mounjaro — approved (2022) to improve glycemic control in adults with type 2 diabetes.
• Zepbound — approved (2023) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition.
• Zepbound for OSA — approved (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, the first drug approved for this use.

Compounded Tirzepatide: Now Legally Restricted

During the 2022–2024 shortage, compounding pharmacies were permitted to make tirzepatide under FDA enforcement discretion. The FDA declared the tirzepatide shortage resolved in December 2024 and ended that discretion in early 2025 (with short transition windows for 503A and 503B pharmacies), and courts have upheld the decision. As a result, routine compounding of tirzepatide is no longer permitted outside narrow, documented clinical exceptions. Consumers should be cautious of any vendor still marketing “compounded” or “research” tirzepatide; BHRC uses FDA-approved products under physician supervision.

A Note for Athletes

Athletes subject to anti-doping rules should confirm status with their governing body before use, and any prescribed use should be handled through the appropriate therapeutic-use process. Regulations change; verify current rules directly with your sport’s authority.

Conclusion

Tirzepatide’s dosing story is really a titration story: start low at 2.5 mg, climb by 2.5 mg no faster than every 4 weeks, and settle at the lowest dose that meets your goal — 5, 10, or 15 mg depending on whether you’re treating weight, blood sugar, or sleep apnea. The slow ladder is the whole point; it is what keeps the medication tolerable and safe. Just as important is knowing that holding or stepping down is a normal, sanctioned part of the process, and that the boxed thyroid warning and other contraindications make physician supervision non-negotiable. Used the way it was studied — under medical direction, alongside lifestyle change — tirzepatide is among the best-validated tools in metabolic medicine.

Ready to find out whether tirzepatide fits your health goals? Schedule a Peptide Therapy Consultation with the Beverly Hills Rejuvenation Center medical team, or explore our physician-supervised tirzepatide therapy program.

Frequently Asked Questions About Tirzepatide Dosing

What is the starting dose of tirzepatide?

The starting dose is 2.5 mg injected under the skin once weekly for the first 4 weeks. This is an initiation dose only — it lets your body adjust to the medication and is not intended as a treatment dose for weight loss or blood-sugar control. Your provider then decides whether to increase it.

How often can the tirzepatide dose be increased?

No more often than every 4 weeks, and only in 2.5 mg increments. The 4-week interval gives your digestive system time to adapt to each new level, which reduces nausea and other gastrointestinal side effects. Increasing faster is the most common avoidable cause of intolerance.

What is the maximum dose of tirzepatide?

The maximum dose is 15 mg once weekly. Many patients never need to reach 15 mg — a lower maintenance dose of 5 or 10 mg often controls appetite, weight, or blood sugar effectively. The goal is the lowest dose that works for you, not the highest possible dose.

What are the maintenance doses for weight loss versus diabetes versus sleep apnea?

For weight loss (Zepbound), maintenance doses are 5, 10, or 15 mg. For type 2 diabetes (Mounjaro), they are also 5, 10, or 15 mg, titrated to blood-sugar targets. For obstructive sleep apnea, the trials used only 10 or 15 mg, so the target is the higher end of the range.

How long does it take to reach the maintenance dose?

Reaching a 5 mg maintenance dose takes about 4 weeks; 10 mg takes roughly 12 weeks; and the 15 mg maximum takes about 20–24 weeks at the fastest label-permitted pace. If any dose is repeated for tolerability, the timeline is longer — which is normal and expected.

What should I do if I can’t tolerate a dose increase?

Contact your provider. Common solutions are to stay at your current well-tolerated dose for extra weeks before trying again, or to step back down to the previous dose and stabilize. Dose reduction is a normal, anticipated part of titration — never push through severe symptoms, and never adjust the dose yourself.

Is 2.5 mg of tirzepatide enough to lose weight?

2.5 mg is a starter dose designed for adjustment, not for results, so meaningful appetite and weight effects usually build at 5 mg and above. If you feel little effect at 2.5 mg, that is expected — judge the medication only after you reach an active maintenance dose under your provider’s guidance.

Is Mounjaro dosing the same as Zepbound dosing?

Yes. Mounjaro and Zepbound are the identical tirzepatide molecule with the same strengths (2.5–15 mg) and the same titration rules. They differ in FDA-approved indication and branding: Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnea.

Can I change the day I inject tirzepatide?

Yes, as long as at least 3 days (72 hours) separate two doses. Tirzepatide is injected once weekly, at any time of day, with or without food. Picking a consistent, memorable day improves adherence, but you can shift it around travel or scheduling when needed.

Is compounded tirzepatide still legal in 2026?

Routine compounding of tirzepatide is now legally restricted. The FDA declared the shortage resolved in December 2024 and ended compounding enforcement discretion in early 2025, and courts upheld that decision. FDA-approved Mounjaro and Zepbound are the appropriate products; be cautious of vendors still selling “compounded” or “research” tirzepatide.

Related Resources from BHRC

• Tirzepatide Therapy at BHRC — physician-supervised program overview.
• Semaglutide Therapy at BHRC — the leading single-agonist GLP-1 alternative.
• Semaglutide Dosage Guide — companion titration guide.
• Retatrutide Dosage Guide — the investigational triple agonist, for education.
• Schedule a Peptide Therapy Consultation — talk to the BHRC medical team.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. Link · PubMed
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519. Link
3. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193–1205. doi:10.1056/NEJMoa2404881. Link · PubMed
4. U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection — Prescribing Information. accessdata.fda.gov
5. U.S. Food and Drug Administration / DailyMed. MOUNJARO (tirzepatide) injection — Prescribing Information. dailymed.nlm.nih.gov
6. U.S. Food and Drug Administration. FDA approves Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). Eli Lilly announcement. Link
7. U.S. Food and Drug Administration. Clarification of policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved; compounding wind-down). fda.gov

Reminder: This content is educational and current as of July 24, 2026. It does not replace personalized medical advice. Tirzepatide is a prescription medication; all dosing decisions must be made and monitored by your licensed healthcare provider.